Article

Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung Cancer

2026-01-23

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> Methylthioadenosine phosphorylase (MTAP) loss co-occurs with actionable genomic alterations in non-small cell lung cancer (NSCLC) and creates vulnerability to protein arginine methyltransferase 5 (PRMT5) inhibition. Estimates of prevalence of MTAP loss rely on next-generation sequencing which can underestimate copy losses. Moreover, the activity of PRMT5 inhibitors in oncoge...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b575bd04-57be-5e17-a504-2b36db214be5
DOI: 10.64898/2026.01.21.700721

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung CancerDOI 10.64898/2026.01.21.700721Read

Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency.Semantic proximity Read

Clinicogenomic Landscape of MTAP-Deleted Thoracic Malignancies Across US and Japanese Nationwide Cohorts: Impact of Concurrent CDKN2A Alterations and Driver Mutations.Semantic proximity Read

Acquired resistance to the PRMT5 inhibitor confers collateral sensitivity to MEK inhibition in MTAP-null non-small cell lung cancerSemantic proximity Read

Prevalence of S-methyl-5'-thioadenosine Phosphorylase (MTAP) Deficiency in Human Cancer: A Tissue Microarray Study on 13,067 Tumors From 149 Different Tumor Types.Semantic proximity Read

Histological characteristics of lung adenocarcinoma with uncommon actionable alterations: special emphasis on MET exon 14 skipping alterations.Semantic proximity Read

Association between methyltransferase-like 3 and non-small cell lung cancer: pathogenesis, therapeutic resistance, and clinical applicationsSemantic proximity Read

Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.Semantic proximity Read

Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.Semantic proximity Read

Comprehensive Genomic and Transcriptomic Characterization of MTAP Loss across Advanced Solid Tumors.Semantic proximity Read

Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in <i>MET</i> exon 14 skipping mutation positive lung cancerSemantic proximity Read

Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer.Semantic proximity Read

Genome Wide Methylome Alterations in Lung Cancer.Semantic proximity Read